Paper Details

  1. Home
  2. Paper Details

A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients.

Author: DikopfAlana, SalgiaRavi, WoodKevin

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

The treatment of non-small cell lung cancer (NSCLC) has advanced with the discovery of oncogenic driver mutations and targeted therapies. Crizotinib, an inhibitor of ALK, MET, and ROS1 receptor tyrosine kinases, is approved for ALK inhibition. It is effective in NSCLC harboring ALK translocations, leading to overexpression of oncogenic ALK fusion proteins.
Paper Details　
Original Abstract of the Article :
In the past decade, the treatment of NSCLC has been revolutionized by the discovery of key oncogenic driver mutations and the therapies that specifically target these mutations. Crizotinib has been shown to be an inhibitor of MET, anaplastic lymphoma kinase (ALK) and ROS1 receptor tyrosine kinases, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14740338.2015.1007040

データ提供：米国国立医学図書館（NLM）

Crizotinib: A Beacon of Hope for ALK-Positive NSCLC

Cancer research is a vast and often challenging landscape, but advancements in targeted therapies offer hope for patients. This study takes us on a journey into the world of non-small cell lung cancer (NSCLC), exploring the potential of crizotinib, a tyrosine kinase inhibitor, as a targeted therapy for ALK-positive NSCLC. The research delves into the safety and efficacy of crizotinib, highlighting its potential to revolutionize the treatment of this type of cancer, much like discovering a hidden oasis in a vast desert.

Targeted Therapy: A Precision Approach to Lung Cancer

Crizotinib has shown promising results in inhibiting ALK, a specific oncogenic driver mutation found in some NSCLC patients. The study highlights the potential of ALK inhibition as a targeted therapy for NSCLC, offering a more personalized approach to treatment. It's like using a map to navigate a desert, pinpointing the exact location of the oasis for effective intervention.

Hope for Lung Cancer Patients

This study offers a glimmer of hope for patients with ALK-positive NSCLC. It emphasizes the importance of identifying specific genetic mutations and tailoring treatment accordingly. The research highlights the potential for targeted therapies to improve patient outcomes and enhance their quality of life, transforming a challenging landscape into a more hopeful one.

Dr. Camel's Conclusion

This research showcases the potential of targeted therapies to revolutionize the treatment of cancer. By understanding the specific genetic mutations driving cancer growth, we can develop more precise and effective treatments, offering a beacon of hope for patients facing a challenging diagnosis. It's like discovering a new technology that transforms our ability to navigate the vast desert of cancer research.

Date :
  1. Date Completed 2015-09-28
  2. Date Revised 2022-03-31
Further Info :

Pubmed ID

25659177

DOI: Digital Object Identifier

10.1517/14740338.2015.1007040

Related Literature

Article Analysis
・Side Effects of crizotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.